The attention deficit hyperactivity disorder (ADHD) treatment Jornay PM (methylphenidate HCI; Ironshore) is now available in the US.
Jornay PM is indicated for patients 6 years of age and older and is intended for dosing in the evening. The treatment utilizes a proprietary drug delivery platform which consists of 2 functional film coatings: the first layer delays the initial drug release for up to 10 hours and the second layer helps control the release rate of the active ingredient throughout the day.
“Several families I work with have developed a number of creative, but often disruptive strategies, like waking up extra early to take medicine in an attempt to improve the early morning routine,” said Dr. Ann Childress, MD, President, Center for Psychiatry and Behavioral Medicine, Las Vegas. “I believe that Jornay PM represents a welcome addition to the therapeutic options.”
Jornay PM is a schedule II (CII) controlled substance and is available in 20mg, 40mg, 60mg, 80mg, and 100mg extended-release capsules. Dosing should be initiated at 8:00pm (the most common dosing time in clinical trials); timing may be adjusted between 6:30pm and 9:30pm to optimize tolerability and efficacy. For patients with difficulty swallowing, the capsule may be opened and the entire contents should be sprinkled onto applesauce and consumed immediately; the beads should not be chewed.
Jornay PM should not be substituted for other methylphenidate products on a milligram-per-milligram basis because these products have different pharmacokinetic profiles and may have different methylphenidate base composition.
For more information visit jornaypm.com.
This article originally appeared on MPR